Delvys Rodríguez-Abreu

17PUBLICATIONS
136CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Mar 06, 2026
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib.

Zofia Piotrowska, Myung-Ju Ahn, Pei Jye Voon

|Jul 29, 2025
Ozone Treatment in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Review of Rationale and Research Directions.

Bernardino Clavo, Angeles Cánovas-Molina, Mario Federico

|Feb 28, 2024
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.

Xiangnan Guan, Ruozhen Hu, Yoonha Choi

|Jan 06, 2024
Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer.

Mariano Provencio-Pulla, Diego Pérez-Parente, Sara Olson

|Aug 21, 2023
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).

Ernest Nadal, Delvys Rodríguez-Abreu, Marta Simó

|Aug 03, 2023
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.

Sarah A Weiss, Mario Sznol, Montaser Shaheen

Pageof 3

Frequent Collaborators

5 joint publications

Javier de Castro Carpeño

5 joint publications

Byoung Chul Cho

4 joint publications

Namrata S Patil

4 joint publications

Barzin Y Nabet